Merck: Phase 3 Study of Antibacterial Recarbrio Meets Key Endpoints

Date : 09/30/2019 @ 11:39AM
Source : Dow Jones News
Stock : Merck and Co Inc (MRK)
Quote : 84.65  0.52 (0.62%) @ 12:59AM
After Hours
Last Trade
Last $ 84.68 ▲ 0.03 (0.04%)

Merck: Phase 3 Study of Antibacterial Recarbrio Meets Key Endpoints

Merck (NYSE:MRK)
Historical Stock Chart

2 Months : From Sep 2019 to Nov 2019

Click Here for more Merck Charts.

By Colin Kellaher


Merck & Co. (MRK) on Monday said a pivotal phase 3 study of its antibacterial product Recarbrio met its main endpoints in adults with hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.

The Kenilworth, N.J., drug maker said Recarbrio met the primary endpoint of statistical non-inferiority compared to piperacillin/tazobactam in day 28 all-cause mortality and the secondary endpoint of clinical response at early follow up in the modified intent-to-treat population.

Merck said it plans to present the full data from the trial at a scientific congress next year.


Write to Colin Kellaher at


(END) Dow Jones Newswires

September 30, 2019 07:24 ET (11:24 GMT)

Copyright (c) 2019 Dow Jones & Company, Inc.

Latest MRK Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Your Recent History
Gulf Keyst..
FTSE 100
UK Sterlin..
Stocks you've viewed will appear in this box, letting you easily return to quotes you've seen previously.

Register now to create your own custom streaming stock watchlist.

NYSE, AMEX, and ASX quotes are delayed by at least 20 minutes.
All other quotes are delayed by at least 15 minutes unless otherwise stated.